All In Biotech

Drug Trial Radar · NCT05727904

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 670 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

670

Planned (sponsor's estimate)

Start

Mar 30, 2023

Primary completion

Mar 1, 2028

Study completion Mar 1, 2030

Sponsor

Lead sponsor
Iovance Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.

Conditions

  • Metastatic Melanoma
  • Unresectable Melanoma
  • Melanoma

Interventions

  • Lifileucel plus PembrolizumabBiological

    A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.

  • Pembrolizumab with Optional Crossover PeriodBiological

    Patient will receive Pembrolizumab monotherapy every 6 weeks until disease progression. Upon verified confirmed disease progression by the blinded independent review central committee, patients may proceed to lifileucel monotherapy during an optional crossover period if they meet eligibility criteria. Optional crossover: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate and Progression Free SurvivalTime frame: 5 years total duration

Locations

82 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham: The Kirklin Clinic

    Birmingham, Alabama · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • California Pacific Medical Center

    San Francisco, California · Withdrawn

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • University of Illinois Hospital & Health Sciences System

    Chicago, Illinois · Withdrawn

  • University of Kansas

    Kansas City, Kansas · Withdrawn

  • University of Louisville - James Graham Brown Cancer Center

    Louisville, Kentucky · Withdrawn

  • National Cancer Institute

    Bethesda, Maryland · Recruiting

  • Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center

    Detroit, Michigan · Withdrawn

  • Henry Ford Health

    Detroit, Michigan · Withdrawn

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Dartmouth-Hitchcock Medical Center (DHMC) - Norris Cotton Cancer Center

    Lebanon, New Hampshire · Recruiting

  • MD Anderson Cancer Center at Cooper

    Camden, New Jersey · Recruiting

  • Oncology Hematology Care

    Cincinnati, Ohio · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • St. Luke's Cancer Center - Anderson

    Easton, Pennsylvania · Withdrawn

  • Allegheny Health Network

    Pittsburgh, Pennsylvania · Recruiting

  • Baptist Cancer Center

    Bartlett, Tennessee · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Intermountain Health

    Salt Lake City, Utah · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Withdrawn

  • Swedish Cancer Institute

    Edmonds, Washington · Recruiting

  • Flinders Medical Centre

    Bedford Park, Australia · Recruiting

  • Westmead Hospital

    Westmead, Australia · Recruiting

  • Greenslopes Private Hospital

    Greenslopes, Queensland, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • Universitair Ziekenhuis Brussel - Oncologisch Centrum

    Jette, Belgium · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Canada · Recruiting

  • Centre hospitalier de l'Université de Montréal

    Montreal, Quebec, Canada · Recruiting

  • Helsinki University Hospital Comprehensive Cancer Center

    Helsinki, Finland, Finland · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Recruiting

  • Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu

    Nantes, France · Recruiting

  • Hopital Saint Louis

    Paris, France · Recruiting

  • Universitätsklinikum Carl Gustav Carus

    Dresden, Germany · Recruiting

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Universitätsklinikum Schleswig-Holstein - Campus Lübeck

    Lübeck, Germany · Recruiting

  • Klinikum Rechts der Isar der Technischen Universität München

    Munich, Germany · Recruiting

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.